What has Pourhassan, Cytodyn, or Lalezari produced?
NOTHING
Case in point--- Cytolin (Hmmm, looks similar to leronlimab, same bullshit story, different name)
CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS
CytoDyn, Inc. is preparing for its next clinical trial of Cytolin, the breakthrough drug for HIV/AIDS that uses the body's own immune system to fight the virus. The preparations come at a time when CytoDyn, Inc. is making big changes that include relocating to a larger facility to accommodate expanded business activities.
SANTA FE, NM (PRWEB) OCTOBER 22, 2008
Although HIV and AIDS are substantially more treatable now than during the height of the AIDS epidemic in the 1980s, numerous challenges still face AIDS and HIV patients and AIDS researchers. One major concern is that drug-resistant strains of HIV are emerging globally, but there is hope that Cytolin, a first-in-class AIDS and HIV treatment from CytoDyn, Inc., can help address this problem.
A new clinical trial to reinvestigate dosing specifications for Cytolin will be conducted in San Francisco, California, by Dr. Jay Lalezari, a leading AIDS researcher. The study will be managed by New York City-based Target Health, Inc., which CytoDyn, Inc. has retained to serve as its contract research organization for the project.
Cytolin is based on a decade of progress in immunology. Community physicians used the drug experimentally at the height of the AIDS epidemic to rescue patients when no effective antiviral treatments had yet been approved for people with AIDS.
"We're excited about the progress we've made in preparing for the next clinical trial of Cytolin," explains Dr. Nadar Pourhassan, Chief Operating Officer of CytoDyn, Inc. "We should soon be prepared to show those unfamiliar with a decade of progress in immunology that science has the solution to multi-drug resistance in HIV/AIDS and, perhaps, other infectious diseases."
Cytolin is a unique treatment for AIDS because it utilizes the immune systems of its users to control HIV infection. Strong immune systems typically control all viruses regardless of their subspecies, which suggests the potential for Cytolin to serve as an effective therapy for HIV/AIDS patients who are failing antiretroviral treatment. The drug may also help suppress drug resistant forms of HIV when used in conjunction with a successfu antiretroviral treatment for AIDS.
Allen D. Allen, Chief Executive Officer of CytoDyn, Inc., says the company philosophy is to maintain complete transparency in its operations. Visitors to CytoDyn.com can view the Company's financial records, share price, and a summary that explains the science behind Cytolin with key references to the literature.
"An enduring recovery of the global economy depends upon capitalists ending their love affair with smoke-and-mirrors, and investing in reality instead of perceptions," says Allen D. Allen, Chief Executive Officer of CytoDyn, Inc. "Unfortunately, innumeracy has to end first, and we hope to contribute to some progress in that regard."
In addition to the upcoming trial of Cytolin, CytoDyn, Inc. is announcing the relocation of its offices to 1511 Third St., Santa Fe, New Mexico. The expanded offices will accommodate new staff members who will be bringing the company's periodic filings up to date.
To learn more about CytoDyn, Inc., the upcoming clinical trials for Cytolin and how Cytolin may be used as an adjunct for antiretroviral treatments for AIDS, visit CytoDyn.com.
The CYDY noise from Vancouver can launch all the red herrings wanted. The Pestell lawsuit states the facts of the matter and an independent ARBITRATION PANEL found Pestell’s version credible and awarded him full compensation and damages.
We will never know what the Pestell venture could have produced for CYDY. NP nuked it almost immediately from the start because Pestell would not bend a knee to HIM AND VIOLATE ETHICAL MATTERS.
It’s on the record, in black and white IN AN ACCOUNT VALIDATED by a independent 3rd party. All else on this decided matter regarding Pestell is just noise.
AND …WAIT FOR IT…NP acknowledged Pestell’s contributions in the video yesterday.
News 
Market Data 
Discover 
AI
